| Q64080404 | Circulating miRNA Signature as a Potential Biomarker for the Prediction of Analgesic Efficacy of Hydromorphone |
| Q37668005 | Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape |
| Q92210407 | Decreased Level of Blood MicroRNA-133b in Men with Opioid Use Disorder on Methadone Maintenance Therapy |
| Q41660414 | Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment |
| Q52595639 | Identification of lncRNA expression profiles and ceRNA analysis in the spinal cord of morphine-tolerant rats. |
| Q47709751 | MiR-5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6. |
| Q38479762 | Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land? |
| Q58730374 | Novel Roles of Non-Coding RNAs in Opioid Signaling and Cardioprotection |
| Q38534875 | Pharmacologic Options for the Treatment of Sarcopenia |
| Q48179184 | Potential Role of Extracellular Vesicles in the Pathophysiology of Drug Addiction |
| Q38825008 | Progress With Nonhuman Animal Models of Addiction |
| Q43689427 | Role of G protein-coupled receptors-microRNA interactions in gastrointestinal pathophysiology. |
| Q64063344 | miR-873a-5p Targets A20 to Facilitate Morphine Tolerance in Mice |
| Q38668241 | microRNA and Pain |